


What is Claimed is:

1. A compound which has the structure



5

wherein x is 1, 2, 3 or 4; m is 1 or 2; n is 1 or 2;

Q is C or N;

A is O or S;

Z is O or a bond;

10 R¹ is H or lower alkyl;

X is CH or N;

R² is H, alkyl, alkoxy, halogen, amino or substituted amino;

15 R^{2a}, R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;


R³ is H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, 20 alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxycarbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, cycloheteroalkyl, heteroarylcarbonyl, heteroaryl-heteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxycarbonylamino, 25 aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroaryl-heteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkyl, aminocarbonyl, substituted aminocarbonyl, 30 alkylaminocarbonyl, arylaminocarbonyl, heteroarylalkenyl, cycloheteroalkylheteroarylalkyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl, arylalkyloxycarbonyl, alkylaryloxycarbonyl, arylheteroarylalkyl, arylalkylarylalkyl, aryloxyarylalkyl, alkynyloxycarbonyl,

haloalkoxyaryloxy carbonyl, alkoxycarbonylaryloxy carbonyl,
 aryloxyaryloxy carbonyl, arylsulfinylaryl carbonyl,
 arylthioaryl carbonyl, alkoxycarbonylaryloxy carbonyl,
 arylalkenyloxy carbonyl, heteroaryloxyarylalkyl,
 5 aryloxyaryl carbonyl, aryloxyarylalkyloxy carbonyl,
 arylalkenyloxy carbonyl, arylalkyl carbonyl,
 aryloxyalkyloxy carbonyl arylalkylsulfonyl,
 arylthiocarbonyl, arylalkenylsulfonyl,
 heteroarylsulfonyl, arylsulfonyl, alkoxyarylalkyl,
 10 heteroarylalkoxy carbonyl, arylheteroarylalkyl,
 alkoxyaryl carbonyl, aryloxyheteroarylalkyl,
 heteroarylalkyloxyarylalkyl, arylarylalkyl,
 arylalkenylarylalkyl, arylalkoxyarylalkyl,
 arylcarbonylarylalkyl, alkylaryloxyarylalkyl,
 15 arylalkoxy carbonyl heteroarylalkyl, heteroarylarylalkyl,
 arylcarbonyl heteroarylalkyl, heteroaryloxyarylalkyl,
 arylalkenyl heteroarylalkyl, arylaminoarylalkyl or
 aminocarbonylarylalkyl;


Y is CO_2R^4 (where R^4 is H or alkyl, or a prodrug
 20 ester) or Y is a C-linked 1-tetrazole, a phosphinic acid
 of the structure $\text{P}(\text{O})(\text{OR}^{4a})\text{R}^5$, (where R^{4a} is H or a prodrug
 ester, R^5 is alkyl or aryl) or a phosphonic acid of the
 structure $\text{P}(\text{O})(\text{OR}^{4a})_2$, (where R^{4a} is H or a prodrug ester);

including all stereoisomers thereof, prodrug
 25 esters thereof, and pharmaceutically acceptable salts
 thereof, with the proviso that where X is CH, A is O, Q
 is C, Z is O and Y is CO_2R^4 , then R^3 is other than H or
 alkyl containing 1 to 5 carbons in the normal chain.


30 2. A compound having the structure



or




3. The compound as defined in Claim 1 having the structure




5

4. The compound as defined in Claim 1 having structure



or

10



5. The compound as defined in Claim 1 wherein (CH₂)_x is alkylene, alkenylene, allenyl, or alkynylene.


15

6. The compound as defined in Claim 4 wherein X is CH.

7. The compound as defined in Claim 4 wherein X is N.


20

8. The compound as defined in Claim 1 having the structure



wherein R¹ is alkyl, R^{3b} is arylalkylamino, aryl-
 5 arylamino, arylamino, alkoxyarylamino, dialkoxyarylamino, dihaloarylamino or alkylthioarylamino.

9. The compound as defined in Claim 1 having the structure



10. The compound as defined in Claim 1 wherein R^{2a} is alkoxy or H,

(CH₂)_x is CH₂, (CH₂)₂, (CH₂)₃, or $\begin{array}{c} \text{CH}_3 \quad \text{CH}_3 \\ \diagdown \quad \diagup \\ \text{---C---} \end{array}$, (CH₂)_m is CH₂, or

15 $\begin{array}{c} \text{R}_a \\ | \\ \text{---CH---} \end{array}$ (where R_a is alkyl or alkenyl), (CH₂)_n is CH₂, R¹ is lower alkyl, preferably -CH₃, R² is H, R^{2a} is H, R⁴ is H, X is CH, and R³ is arylalkyloxycarbonyl, arylheteroaryalkyl, aryloxyaryalkyl, arylalkyl, aryloxycarbonyl, haloaryl-oxycarbonyl,
 20 alkoxyaryloxycarbonyl, alkylaryloxycarbonyl, aryloxyaryloxycarbonyl, heteroaryloxyaryalkyl, heteroaryloxycarbonyl, aryloxyarylcarbonyl, arylalkenyloxycarbonyl, cycloalkylaryloxycarbonyl, arylalkylarylcarbonyl, heteroaryl-heteroarylalkyl,
 25 cycloalkyloxyaryloxycarbonyl, heteroaryl-heteroarylcarbonyl, alkyloxyaryloxycarbonyl, arylalkylsulfonyl, arylalkenylsulfonyl, alkoxyaryalkyl, arylthiocarbonyl, cycloheteroalkylalkyloxycarbonyl, cycloheteroalkyloxycarbonyl, or polyhaloalkylaryloxy-
 30 carbonyl, which may be optionally substituted.


11. The compound as defined in Claim 5 wherein X is CH.

5 12. The compound as defined in Claim 5 wherein X is N.


13. The compound as defined in Claim 1 wherein x is 2, m is 1, and n is 1.

10

14. The compound as defined in Claim 1 having the structure






15 15. The compound as defined in Claim 1 having the structure



where $(CH_2)_n$ is CH_2 or $\begin{array}{c} CH_3 \\ | \\ -CH- \end{array}$.


16. The compound as defined in Claim 1 having the structure






, where $R^3 =$


5





10





15









5





10




15









5







10





15











5




10









15







, where R^{3d} =




5





10





15










5





10





15









5







10





15















10




15










5









10

, where R^{3e} =



15












15




5








10






15









10





15



, where $R^3 =$





where $R^3 =$




, where $R^3 =$








5









10







15










5






10






5





10






15





















5






10









10







5















10









5



10

























[illegible]






















5


17. The compound as defined in Claim 1 having the structure





























5




18. The compound as defined in Claim 1 having the structure





10











19. The compound as defined in Claim 1 having the structure








20. The compound as defined in Claim 1 having the structure







15











5








10










5





10









5











10


















5








10











CC1=C(C(=N1)C2=CC=CC=C2)CCCC3=CC=C(C=C3)CN(CCC(=O)OC4=CC=C(OC)C=C4)CC(=O)O









5


















10













5









5






21. The compound as defined in Claim 1 having the
5 structure




22. The compound as defined in Claim 1 having the
structure




10


23. The compound as defined in Claim 1 having the
structure




24. The compound as defined in Claim 1 having the structure




25. The compound as defined in Claim 1 having the structure



26. The compound as defined in Claim 1 having the structure




27. The compound as defined in Claim 1 having the structure




5

28. The compound as defined in Claim 1 having the structure




10

29. The compound as defined in Claim 1 having the structure




15

30. The compound as defined in Claim 1 having the structure




31. The compound as defined in Claim 1 having the structure



5

32. The compound as defined in Claim 1 having the structure



10

33. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

15

34. A method for lowering blood glucose levels which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

20

35. A method for treating diabetes which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

25

36. A method for treating a premalignant disease, an early malignant disease, a malignant disease, or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

37. A pharmaceutical combination comprising a compound as defined in Claim 1 and a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent, a platelet aggregation inhibitor, and/or an antiosteoporosis agent.

38. The pharmaceutical combination as defined in Claim 37 comprising said compound and an antidiabetic agent.

39. The combination as defined in Claim 38 wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR α agonist, a PPAR γ agonist, a PPAR α/γ dual agonist, an SGLT2 inhibitor, a DP4 inhibitor, an α P2 inhibitor, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), insulin and/or a meglitinide.

40. The combination as defined in Claim 39 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyrider, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl-262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, P32/98 and/or NVP-DPP-728A.

41. The combination as defined in Claim 38 wherein the compound is present in a weight ratio to the antidiabetic agent within the range from about 0.001 to about 100:1.

42. The combination as defined in Claim 37 wherein the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake

inhibitor, a thyroid receptor agonist, an α P2 inhibitor and/or an anorectic agent.

43. The combination as defined in Claim 42 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol.

44. The combination as defined in Claim 37 wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor.

45. The combination as defined in Claim 44 wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, itavastatin, visastatin, fenofibrate, gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, cholestagel, niacin and/or LY295427.

46. The combination as defined in Claim 44 wherein the compound is present in a weight ratio to the lipid-lowering agent within the range from about 0.001:1 to about 100:1.

47. The combination as defined in Claim 37 wherein the antihypertensive agent is an ACE inhibitor, angiotensin II receptor antagonist, NEP/ACE inhibitor, calcium channel blocker and/or β -adrenergic blocker.

48. The combination as defined in Claim 47 wherein the antihypertensive agent is an ACE inhibitor which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril; an NEP/ACE inhibitor which is omapatrilat, [S[(R*,R*)]-hexahydro-6-

[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat) or CGS 30440;

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;

5 amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or clonidine HCl.

49. The combination as defined in Claim 37 wherein
10 the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or ifetroban.

50. A method for treating insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels
15 of free fatty acids or glycerol, hyperlipidemia, obesity, Syndrome X, dysmetabolic syndrome, inflammation, diabetic complications, impaired glucose homeostasis, impaired glucose tolerance, hypertriglyceridemia or atherosclerosis which comprises administering to a
20 mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 43.

51. A method for treating irritable bowel
25 syndrome, Crohn's disease, gastric ulceritis or osteoporosis, or psoriasis, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

30 52. The method as defined in Claim 36 wherein the disease is a liposarcoma or an epithelial tumor.

53. The method as defined in Claim 52 wherein the
35 epithelial tumor is a tumor of the breast, prostate, colon, ovaries, stomach or lung.

54. The method as defined in Claim 36 wherein the disease is ductal carcinoma in situ of the breast, lobular carcinoma in situ of the breast, fibroadenoma of the breast, or prostatic intraepithelial neoplasia.

5